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CORRESPONDENCE
Letters to the Editor
Visipaque (Iodixanol)
and Hexabrix (Ioxaglate)
in Renal Insufficiency
I read with great interest the RECOVER (Renal Toxicity Eval-
uation and Comparison Between Visipaque and Hexabrix in
Patients With Renal Insufficiency Undergoing Coronary Angiog-
raphy) study by Jo et al. (1). They compared the renal tolerance of
iodixanol and ioxaglate in patients with renal insufficiency after
coronary angiography. They found that the incidence of contrast-
induced nephropathy (CIN) was lower in the iodixanol group
(7.9%) as compared with the ioxaglate group (17%) (p  0.021).
I would be interested in obtaining some details as to why
substantial differences exist in the number of patients presented in
different meetings (n 281) (2,3) and in the final publication (n
275). In this regard, I also do not understand how 164 and 117
patients for the iodixanol and the ioxaglate groups, respectively,
may have been presented in previous meetings while the plan’s
sample size was 150 patients in each group with a permuted
block-randomization method.
Also, an intention-to-treat analysis would seem more appropriate
than a per-protocol analysis. Furthermore, among risk factors that
might have influenced the results, age (4) and hydration status (5,6)
are crucial. Patients were older in the ioxaglate group (68.7 7.5 years
vs. 66.1  8.6 years; p  0.01). Although the investigators indicate
that the difference is likely to be too small to be relevant it may still
represent a bias that may explain at least partially their results. Volume
supplementation remains the cornerstone for the prevention of CIN.
Hydration status was not assessed and/or not presented. Body weight,
diuresis, and volume given to the patients should be indicated to
ensure comparability between groups.
Finally, CIN remains a major health issue. Only one study (7) has
shown in diabetic patients with renal insufficiency that iodixanol is
less nephrotoxic than iohexol. Further trials should be conducted
to assess the comparative renal tolerance of low osmolar contrast
media (both ionic and nonionic) and nonionic dimers.
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Evaluation and Comparison
Between Visipaque (Iodixanol)
and Hexabrix (Ioxaglate)
in Coronary Angiography
We read with interest the report by Jo et al. (1). The reported
head-to-head study (RECOVER [Renal Toxicity Evaluation and
Comparison Between Visipaque and Hexabrix in Patients With
Renal Insufficiency Undergoing Coronary Angiography]) compares
the renal tolerance of the iso-osmolar contrast medium (CM) iodixa-
nol to the low-osmolar CM ioxaglate using established surrogate
definitions for contrast-induced nephropathy (CIN). Jo et al. (1)
believe the results of the RECOVER study support the conclusions of
the NEPHRIC (Nephrotoxic Effects in High-Risk Patients Under-
going Angiography) study (2), which created the hypothesis that
iso-osmolar CM are superior regarding CIN as compared to the
well-established low-osmolar contrast media (LOCM). To date, the
NEPHRIC study was never confirmed in a larger series, a fact that
has increasingly raised concerns (3).
The results of RECOVER are in complete disagreement with the
results of our recent registry analysis in over 57,000 patients (4). The
latter study clearly demonstrates a higher incidence of actual renal
failure after iodixanol application as compared to ioxaglate or iohexol
application. We note that the RECOVER study includes more
patients (n  275) than the NEPHRIC study (n  129), but taking
the reported figures of the RECOVER study at face value one cannot
fail to notice some inconsistencies in the results. The broad surrogate
definition of CIN, 25% relative or 0.5 mg/dl increase over baseline,
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reaches significance in the RECOVER study (p  0.021); however,
the 2 more stringent surrogate definitions that were used in the
NEPHRIC study (0.5 mg/dl; 1.0 mg/dl increase over baseline)
both did not reach significance. Thus, in terms of statistical
significance the RECOVER study does not confirm the NEPHRIC
study (i.e., no beneficial effect of iso-osmolar CM over LOCM).
Regarding outcome end points, the RECOVER study actually
shows no, let alone significant, differences between the agents.
Acute renal failure requiring dialysis occurred only once in both the
iodixanol and the ioxaglate groups. One can argue that the more
stringent/relevant the end points the less or even nonexistent are
the differences between the 2 groups in the RECOVER study.
Still, the RECOVER study results seem to contradict the findings
of our registry study, as the outcome end points showed no
differences between the agents. However, the size of the RE-
COVER study with 275 patients is much too small to detect
differences between the rarely occurring outcome events.
Our registry study, conversely, included over 57,000 patients, a
size adequate to detect such small differences in an important end
point as acute renal failure. Finally, we notice a discrepancy
between the patient numbers in the groups published in a previous
abstract on the RECOVER study (5) where the iodixanol group
had some 20 patients more and the ioxaglate group had some 20
patients less, which may interfere with the investigators’ analysis.
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Reply
We thank Dr. Deray and Dr. Persson and colleagues for giving us an
opportunity to clarify the reason behind sample size discrepancy
between published RECOVER (Renal Toxicity Evaluation and
Comparison Between Visipaque [Iodixanol] andHexabrix [Ioxaglate]
in Patients With Renal Insufficiency Undergoing Coronary Angiog-
raphy) and abstracts presented in scientific meetings (1–3) and to
explain some issues.
Persson et al. (4) reported the finding of iodixanol inferiority
contrary to that of the RECOVER study. However, the study by
Persson et al. (4) was a retrospective study that had many compound-
ing factors influencing results. The researchers did not present the
basal serum creatinine and contrast dose of all patients, and the
baseline characteristics of study groups were significantly different.
Most importantly, previous renal failure, prior dialysis, ST-segment
elevation myocardial infarction (STEMI), and unstable coronary
diseases were more frequent in the iodixanol group, all of which were
very critical determinants in developing contrast-induced nephropathy
(CIN) and affecting clinical outcomes. We do not agree with Persson
et al. (4) because of these critical limitations.
We showed a trend of lower CIN incidence in iodixanol by the
more stringent criteria (serum creatinine increase 0.5 mg/dl) as
in the NEPHRIC (Nephrotoxicity in High-Risk Patients Study of
Iso-Osmolar and Low-Osmolar Non-Ionic Contrast Media) (5)
despite failure to reach statistical significance (3.6% vs. 8.9%, p 
0.067). We disagree with the view of Dr. Persson and colleagues
that iso-osmolar contrast media had no beneficial effect over
low-osmolar contrast media owing to a p value of 0.067. Other
investigations support the superiority of iodixanol, such as Chalmers’
study, the NEPHRIC study, and recent meta-analyses (6,7).
Regarding the different sample size, only preliminary data of the
RECOVER study were shown in scientific meetings, and registry
data collected during the same period that the RECOVER study was
conducted were erroneously incorporated into randomization data.
Therefore, the iodixanol group was asymmetrically larger, and total
patient population was higher in abstracts of scientific meetings.
We agree withDr.Deray’s comment that it would be better to present
both intention-to-treat and per-protocol analyses. However, many inves-
tigators presented their data only by per-protocol analysis (8). Moreover,
both analyses made no differences in the RECOVER trial.
We already addressed the issues regarding different age and
similar clinical outcomes of our study. Some studies reported age
over 75 as the risk factor of CIN (9). In the RECOVER study, the
mean age of both groups was under 75 years, and the proportion
of patients over 75 was 18% in the iodixanol group and 22% in the
ioxaglate group, with no difference (p 0.451). We do not believe
that the age difference influenced our results.
Finally, all patients in the RECOVER study received adequate
periprocedural hydration, and the body weight was similar in the 2
groups, as depicted in the study. Although the exact level of hydration
was only available in some patients, volume status was evaluated by
both physical examination and laboratory test in all patients. There-
after, dehydrated and acute renal-failure patients were excluded.
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